Table 2.
Differences in physician and pharmacist nephrotoxicity ratings
| Medication | Physician rating | Pharmacist rating | Medication | Physician rating | Pharmacist rating |
|---|---|---|---|---|---|
| Amikacin | 3 | 2 | Hydroxyurea | 1 | 0 |
| Amoxicillin | 1 | 0 | Imipenem/cilistatin | 1 | 0 |
| Ampcillin/sulbactam | 1 | 0 | Lacosamide | 1 | 0 |
| Amoxicillin-clavulanate | 1 | 0 | Lansoprazole | 1 | 0 |
| Cefazolin | 1 | 0 | Meropenem | 1 | 0 |
| Cefotaxime | 1 | 0 | Methylprednisolone | 0 | 1 |
| Cefotetan | 1 | 0 | Naproxen | 3 | 2 |
| Cefoxitin | 1 | 0 | Nitrofurantoin | 1 | 0 |
| Ceftazidime | 1 | 0 | Pantoprazole | 1 | 0 |
| Cefuroxime | 1 | 0 | Penicillin (G or vK) | 1 | 0 |
| Celecoxib | 3 | 1 | Propylthiouracil | 1 | 0 |
| Cisplatin | 3 | 2 | Pyrazinamide | 1 | 0 |
| Colistin | 3 | 2 | Rifampin | 1 | 0 |
| Daptomycin | 2 | 1 | Streptomycin | 1 | 3 |
| Diclofenac | 3 | 2 | Sulfamethoxazole/trimethoprim | 1 | 2 |
| Doripenem | 1 | 0 | Tobramycin | 3 | 2 |
| Ertapenem | 1 | 0 | Valganciclovir | 2 | 1 |
| Ethambutol | 1 | 0 | Vancomycin | 3 | 2 |
| Flucytosine | 0 | 1 | Voriconazole | 2 | 0 |
| Foscarnet | 3 | 2 | Zidovudine | 1 | 0 |
| Hydroxychloroquine | 1 | 0 |
Notes: Nephrotoxicity ratings provided for medications where physician and pharmacist ratings differed. Medications not listed received the same consensus ratings by both physicians and pharmacists. Ratings provided are the most commonly reported responses in each clinician group during the round the medication reached consensus. Excludes medications where the consensus rating was “Unknown or Not used in Critical Care” and medications where both clinician groups reported the same ratings. In the instance of a tie, the higher of the two ratings is provided. Rating definitions are as follows: 0 = no nephrotoxic potential in almost all situations, 1 = nephrotoxic potential possible but rare, 2 = nephrotoxic potential probable within routine use, 3 = nephrotoxic potential definite within routine use